Mobile menu icon
Mobile menu icon Search iconSearch
Search type


We offer an infrastructure of staff and expertise to help our industrial partners discover, develop and implement biomarker tests and molecular pathology approaches.

SBDC and MMPathIC are open to approaches from potential industry partners with whom we may be able to develop new collaborations.

Both centres have a strong track record of fruitful industrial dialogue, and are happy to host company visits to our joint space. We will ensure that the most appropriate University and clinical staff are present to discuss your particular business needs.

Manchester Molecular Pathology Innovation Centre (MMPathIC)

MMPathIC can provide support for industry partners and commercial companies via the node infrastructure (health economics, GCLP validation/ verification labs, text mining and health informatics) and linkage to NHS clinical expertise and pathology/genetic service laboratories.

Specifically, MMPathIC can advise on accessing:

  • clinical and pathology expertise;
  • samples and patient cohorts;
  • health economics and health/bio-informatics support;
  • GCLP validation/verification for protein biomarkers (with the Stoller Biomarker Discovery Centre);
  • a route into NHS pathology laboratories;
  • regulatory and commissioning advice;
  • advice on evidence needed for a successful diagnostic development project;
  • support for funding applications;
  • the wider molecular pathology node network.

To request a meeting with the MMPathIC team, please send the following form to and a member of the team will get back to you shortly. 

Stoller Biomarker Discovery Centre (SBDC)

SBDC is funded by a philanthropic donation from the Stoller Charitable Trust, the Medical Research Council and developed in partnership with SCIEX (who provided a large suite of 13 high-end mass spectrometers). The Centre is one of the biggest clinical proteomics facilities in the world focussing on biomarker development and the largest in Europe.

Researchers at SBDC help to industrialise the process of identifying biomarkers, aiding in the translation of biomarkers into the clinical lab.  

Manchester Molecular Pathology Innovation Centre continues to build excellent links with industry, furthering their ambitions to efficiently support the translation of new tests to the clinic for the benefit of patients and companies alike.

Professor Paul Townsend / Associate Dean for Business Engagement, Faculty of Biology, Medicine and Health